214 related articles for article (PubMed ID: 32332049)
1. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
[TBL] [Abstract][Full Text] [Related]
2. NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization.
Narang S; Evensen NA; Saliba J; Pierro J; Loh ML; Brown PA; Kolekar P; Mulder H; Shao Y; Easton J; Ma X; Tsirigos A; Carroll WL
Genome Biol; 2023 Apr; 24(1):64. PubMed ID: 37016431
[TBL] [Abstract][Full Text] [Related]
3. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
Jaffe JD; Wang Y; Chan HM; Zhang J; Huether R; Kryukov GV; Bhang HE; Taylor JE; Hu M; Englund NP; Yan F; Wang Z; Robert McDonald E; Wei L; Ma J; Easton J; Yu Z; deBeaumount R; Gibaja V; Venkatesan K; Schlegel R; Sellers WR; Keen N; Liu J; Caponigro G; Barretina J; Cooke VG; Mullighan C; Carr SA; Downing JR; Garraway LA; Stegmeier F
Nat Genet; 2013 Nov; 45(11):1386-91. PubMed ID: 24076604
[TBL] [Abstract][Full Text] [Related]
4. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
[TBL] [Abstract][Full Text] [Related]
5. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
8. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
[TBL] [Abstract][Full Text] [Related]
9. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X; Edmonson M; Yergeau D; Muzny DM; Hampton OA; Rusch M; Song G; Easton J; Harvey RC; Wheeler DA; Ma J; Doddapaneni H; Vadodaria B; Wu G; Nagahawatte P; Carroll WL; Chen IM; Gastier-Foster JM; Relling MV; Smith MA; Devidas M; Guidry Auvil JM; Downing JR; Loh ML; Willman CL; Gerhard DS; Mullighan CG; Hunger SP; Zhang J
Nat Commun; 2015 Mar; 6():6604. PubMed ID: 25790293
[TBL] [Abstract][Full Text] [Related]
10. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
[TBL] [Abstract][Full Text] [Related]
11. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
12. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
13.
Contreras Yametti GP; Robbins G; Chowdhury A; Narang S; Ostrow TH; Kilberg H; Greenberg J; Kramer L; Raetz E; Tsirigos A; Evensen NA; Carroll WL
Leuk Lymphoma; 2024 Jan; 65(1):78-90. PubMed ID: 37874744
[TBL] [Abstract][Full Text] [Related]
14. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
15. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
16. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
Zhu L; Yu CL; Zheng Y
Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
[TBL] [Abstract][Full Text] [Related]
17. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
18. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance.
Saint Fleur-Lominy S; Evensen NA; Bhatla T; Sethia G; Narang S; Choi JH; Ma X; Yang JJ; Kelly S; Raetz E; Harvey RC; Willman C; Loh ML; Hunger SP; Brown PA; Getz KM; Meydan C; Mason CE; Tsirigos A; Carroll WL
Cancer Res; 2020 Dec; 80(23):5189-5202. PubMed ID: 33067268
[TBL] [Abstract][Full Text] [Related]
20. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
Jones CL; Gearheart CM; Fosmire S; Delgado-Martin C; Evensen NA; Bride K; Waanders AJ; Pais F; Wang J; Bhatla T; Bitterman DS; de Rijk SR; Bourgeois W; Dandekar S; Park E; Burleson TM; Madhusoodhan PP; Teachey DT; Raetz EA; Hermiston ML; Müschen M; Loh ML; Hunger SP; Zhang J; Garabedian MJ; Porter CC; Carroll WL
Blood; 2015 Nov; 126(19):2202-12. PubMed ID: 26324703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
